Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $9.40 in the last session, up 3.07% from day before closing price of $9.12. In other words, the price has increased by $3.07 from its previous closing price. On the day, 5.7 million shares were traded. IOVA stock price reached its highest trading level at $9.63 during the session, while it also had its lowest trading level at $9.17.
Ratios:
We take a closer look at IOVA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.90 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Buy rating and assigned the stock a target price of $17.
On July 29, 2024, Piper Sandler Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $19 to $10.
On November 20, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $12.Goldman initiated its Buy rating on November 20, 2023, with a $12 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Maynard Ryan D sold 50,000 shares for $10.06 per share. The transaction valued at 503,000 led to the insider holds 7,500 shares of the business.
Maynard Ryan D bought 50,000 shares of IOVA for $503,104 on Nov 12 ’24. On Feb 20 ’24, another insider, MCPEAK MERRILL A, who serves as the Director of the company, bought 250,000 shares for $9.15 each. As a result, the insider paid 2,287,500 and bolstered with 320,150 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 2864941312 and an Enterprise Value of 2546394368. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.50 while its Price-to-Book (P/B) ratio in mrq is 3.70. Its current Enterprise Value per Revenue stands at 28.026 whereas that against EBITDA is -6.236.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is -4.66%, while the 200-Day Moving Average is calculated to be -12.80%.
Shares Statistics:
According to the various share statistics, IOVA traded on average about 6.30M shares per day over the past 3-months and 9372750 shares per day over the past 10 days. A total of 256.14M shares are outstanding, with a floating share count of 246.97M. Insiders hold about 18.97% of the company’s shares, while institutions hold 68.45% stake in the company. Shares short for IOVA as of 1731628800 were 53988814 with a Short Ratio of 8.57, compared to 1728950400 on 60338267. Therefore, it implies a Short% of Shares Outstanding of 53988814 and a Short% of Float of 19.580000000000002.
